Joinn’s profit figures spark market outbreak of “monkey fever”
Projected earnings at the drug research company have been inflated by the soaring value of research monkeys, but the on-paper gains may not be sustainable Key Takeaways: Joinn Laboratories uses…
Recent Articles
Joinn’s profit figures spark market outbreak of “monkey fever”
6127.HK
603127.SHG
RELATED ARTICLES
-
Joinn’s ‘jumping’ monkey market hides core weakness
6127.HK603127.SHG - U.S. tries ‘monkey scaring’ to rid Wall Street of suspicious Chinese listings
- Insilico revenue soars above $100 million on AI drug partnerships
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Ganfeng rediscovers profitability as volatile lithium prices test its mettle
002460.SHE
- A healthy return: drug spin-off nets Keymed up to $320 million
-
Razor-thin margins slice holes in Leapmotor’s inaugural profit
9863.HK
